特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
920000

抗体受託製造の世界市場:2020年~2030年

Antibody Contract Manufacturing Market, 2020 - 2030

出版日: | 発行: ROOTS ANALYSIS | ページ情報: 英文 305 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.56円
抗体受託製造の世界市場:2020年~2030年
出版日: 2020年01月31日
発行: ROOTS ANALYSIS
ページ情報: 英文 305 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体受託製造市場は、競争が激しく、あらゆる規模の企業、その一部は、抗体開発から商業生産に至るまで、エンドツーエンドのソリューションの提供が求められています。

当レポートでは、世界の抗体受託製造市場について調査分析し、現在の市場状況と将来の機会について、体系的な情報を提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場情勢

  • 章の概要
  • 抗体受託製造業者:全体の市場情勢

第5章 企業の競合分析

  • 章の概要
  • 前提条件とキー入力パラメーター
  • 手法
  • 企業の競合分析:北米の抗体受託製造業者
  • 企業の競合分析:欧州の抗体受託製造業者
  • 企業の競合分析:アジアの抗体受託製造業者

第6章 企業プロファイル

  • 章の概要
  • AGC Biologics
  • Aldevron
  • BioXcellence (Boehringer Ingelheim)
  • FUJIFILM Diosynth Biotechnologies
  • Lonza
  • Merck
  • Novasep
  • Samsung BioLogics
  • Synthon

第7章 ケーススタディ:低分子薬・高分子薬 (生物製剤) /療法の比較

  • 章の概要
  • 低分子薬と生物製剤

第8章 ベンチマーク分析

  • 章の概要
  • 手法
  • 地域別のベンチマーキング
    • 北米
    • 欧州
    • アジア
  • 結論

第9章 パートナーシップ

  • 章の概要
  • パートナーシップモデル
  • 抗体受託製造:パートナーシップのリスト

第10章 最近の事業拡大

  • 章の概要
  • 抗体受託製造業者:事業拡大のリスト

第11章 生産能力分析

  • 章の概要
  • 前提条件と手法
  • 抗体受託製造業者:世界の設備容量
  • 結論

第12章 需要分析

  • 章の概要
  • 前提条件と手法
  • 抗体受託製造市場:全体の年間需要

第13章 市場規模・機会分析

  • 章の概要
  • 前提条件と予測手法
  • 抗体受託製造市場全体
  • 抗体受託製造市場 - 分布:抗体の種類別
  • 抗体受託製造市場 - 分布:企業規模別
  • 抗体受託製造市場 - 分布:経営規模別
  • 抗体受託製造市場 - 分布:使用する発現系別
  • 抗体受託製造市場 - 分布:地域別

第14章 SWOT分析

第15章 抗体CMO市場の将来

第16章 インタビュー

第17章 付録1:抗体カスタムメーカーのリスト

第18章 付録2:表集計データ

第19章 付録3:企業・組織のリスト

図表

List Of Figuers

  • Figure 3.1. Historical Milestones Related to the Discovery of Antibodies
  • Figure 3.2. Structure of an Antibody
  • Figure 3.3. Mechanism of Action of Antibodies
  • Figure 3.4. Monoclonal Antibody Production
  • Figure 3.5. Symmetric and Asymmetric Bispecific Antibodies
  • Figure 3.6. Mechanism of Action of Bispecific Antibodies
  • Figure 3.7. Polyclonal Antibody Production
  • Figure 3.8. Applications of Polyclonal Antibodies
  • Figure 3.9. Types of Third Party Service Providers
  • Figure 4.1. Antibody Contract Manufacturers: Distribution by Year of Establishment
  • Figure 4.2. Antibody Contract Manufacturers: Distribution by Company Size
  • Figure 4.3. Antibody Contract Manufacturers: Distribution by Scale of Operation
  • Figure 4.4. Antibody Contract Manufacturers: Distribution by Location of Headquarters(Region-wise)
  • Figure 4.5. Antibody Contract Manufacturers: Distribution by Location of Headquarters(Country-wise)
  • Figure 4.6. Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 4.7. Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
  • Figure 4.8. Antibody Contract Manufacturers: Distribution by Expression Systems Used
  • Figure 4.9. Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
  • Figure 4.10. Antibody Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
  • Figure 5.1. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
  • Figure 5.2. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
  • Figure 5.3. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia
  • Figure 6.1. AGC Biologics: Service Portfolio
  • Figure 6.2. Aldevron: Service Portfolio
  • Figure 6.3. BioXcellence(Boehringer Ingelheim): Service Portfolio
  • Figure 6.4. FUJIFILM Diosynth Biotechnologies: Service Portfolio
  • Figure 6.5. Lonza: Service Portfolio
  • Figure 6.6. Merck: Service Portfolio
  • Figure 6.7. Novasep: Service Portfolio
  • Figure 6.8. Samsung BioLogics: Service Portfolio
  • Figure 6.9. Synthon: Service Portfolio
  • Figure 7.1. Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019(till August)
  • Figure 7.2. Comparison of Key Characteristics of Small Molecules and Biologics
  • Figure 7.3. Comparison of Manufacturing Processes of Small Molecules and Biologics
  • Figure 8.1. Benchmark Analysis: Distribution by Region and Company Size
  • Figure 8.2. Benchmark Analysis: North America, Peer Group I
  • Figure 8.3. Benchmark Analysis: North America, Peer Group II
  • Figure 8.4. Benchmark Analysis: North America, Peer Group III
  • Figure 8.5. Benchmark Analysis: Europe, Peer Group IV
  • Figure 8.6. Benchmark Analysis: Europe, Peer Group V
  • Figure 8.7. Benchmark Analysis: Europe, Peer Group VI
  • Figure 8.8. Benchmark Analysis: Asia, Peer Group VII
  • Figure 8.9. Benchmark Analysis: Asia, Peer Group VIII
  • Figure 8.10. Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
  • Figure 9.1. Partnerships: Distribution by Year of Partnership
  • Figure 9.2. Partnerships: Distribution by Type of Partnership
  • Figure 9.3. Partnerships: Distribution by Year and Type of Partnership
  • Figure 9.4. Partnerships: Distribution by Type of Antibody
  • Figure 9.5. Partnerships: Distribution by Project Scale
  • Figure 9.6. Partnerships: Distribution by Focus Therapeutic Area
  • Figure 9.7. Partnerships: Most Active Players
  • Figure 9.8. Partnerships: Country-wise Distribution
  • Figure 9.9. Partnerships: Continent-wise Distribution
  • Figure 10.1. Recent Expansions: Distribution by Year of Expansion
  • Figure 10.2. Recent Expansions: Distribution by Type of Expansion
  • Figure 10.3. Recent Expansions: Distribution by Type of Antibody
  • Figure 10.4. Recent Expansions: Distribution by Type of Antibody and Expansion
  • Figure 10.5. Recent Expansions: Distribution by Location of Facility(Region-wise)
  • Figure 10.6. Recent Expansions: Distribution by Location of Facility(Country-wise)
  • Figure 10.7. Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
  • Figure 10.8. Recent Expansions: Most Active Players
  • Figure 10.9. Recent Expansions: Distribution by Local and International Expansions
  • Figure 11.1. Antibody Contract Manufacturing: Installed Global Capacity
  • Figure 11.2. Antibody Contract Manufacturing Capacity: Distribution by Company Size
  • Figure 11.3. Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
  • Figure 11.4. Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
  • Figure 12.1. Demand Analysis: Annual Demand for Antibodies
  • Figure 12.2. Demand Analysis: Annual Demand for Clinical Scale Operations
  • Figure 12.3. Demand Analysis: Annual Demand for Commercial Scale Operations
  • Figure 12.4. Demand Analysis: Annual Demand in North America
  • Figure 12.5. Demand Analysis: Annual Demand in Europe
  • Figure 12.6. Demand Analysis: Annual Demand in Asia
  • Figure 13.1. Overall Antibody Contract Manufacturing Market, 2020-2030
  • Figure 13.2. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody(USD Billion)
  • Figure 13.3. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size(USD Billion)
  • Figure 13.4. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation(USD Billion)
  • Figure 13.5. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used(USD Billion)
  • Figure 13.6. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography(USD Billion)
  • Figure 13.7. Antibody Contract Manufacturing Market in North America, 2020-2030(USD Billion)
  • Figure 13.8. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies(USD Billion)
  • Figure 13.9. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies(USD Billion)
  • Figure 13.10. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies(USD Billion)
  • Figure 13.11. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations(USD Billion)
  • Figure 13.12. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations(USD Billion)
  • Figure 13.13. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations(USD Billion)
  • Figure 13.14. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations(USD Billion)
  • Figure 13.15. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations(USD Billion)
  • Figure 13.16. Antibody Contract Manufacturing Market in Europe, 2020-2030(USD Billion)
  • Figure 13.17. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies(USD Billion)
  • Figure 13.18. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies(USD Billion)
  • Figure 13.19. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies(USD Billion)
  • Figure 13.20. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations(USD Billion)
  • Figure 13.21. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations(USD Billion)
  • Figure 13.22. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations(USD Billion)
  • Figure 13.23. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations(USD Billion)
  • Figure 13.24. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations(USD Billion)
  • Figure 13.25. Antibody Contract Manufacturing Market in Asia, 2020-2030(USD Billion)
  • Figure 13.26. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies(USD Billion)
  • Figure 13.27. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies(USD Billion)
  • Figure 13.28. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies(USD Billion)
  • Figure 13.29. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations(USD Billion)
  • Figure 13.30. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations(USD Billion)
  • Figure 13.31. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations(USD Billion)
  • Figure 13.32. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations(USD Billion)
  • Figure 13.33. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations(USD Billion)
  • Figure 14.1. Antibody Contract Manufacturing: SWOT Analysis
  • Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Table

  • Table 3.1. Key Features of Antibody Isotypes
  • Table 3.2. Mechanism of Action of Therapeutic Antibodies against Important Target Classes
  • Table 3.3. List of Approved Monoclonal Antibodies
  • Table 3.4. Differences between Monoclonal and Polyclonal Antibodies
  • Table 4.1. List of Antibody Contract Manufacturers
  • Table 4.2. Antibody Contract Manufacturers: Information on Type of Antibodies Manufactured
  • Table 4.3. Antibody Contract Manufacturers: Information on Scale of Operation
  • Table 4.4. Antibody Contract Manufacturers: Information on Expression Systems Used
  • Table 4.5. Antibody Contract Manufacturers: Information on Fill / Finish Services Offered
  • Table 4.6. Antibody Contract Manufacturers: Information on Regulatory Accreditations / Certifications
  • Table 6.1. AGC Biologics: Company Overview
  • Table 6.2. AGC Biologics: Overview of Manufacturing Capabilities
  • Table 6.3. AGC Biologics: Future Outlook
  • Table 6.4. Aldevron: Company Overview
  • Table 6.5. Aldevron: Overview of Manufacturing Capabilities
  • Table 6.6. Aldevron: Future Outlook
  • Table 6.7. BioXcellence(Boehringer Ingelheim): Company Overview
  • Table 6.8. BioXcellence(Boehringer Ingelheim): Overview of Manufacturing Capabilities
  • Table 6.9. BioXcellence(Boehringer Ingelheim): Future Outlook
  • Table 6.10. FUJIFILM Diosynth Biotechnologies: Company Overview
  • Table 6.11. FUJIFILM Diosynth Biotechnologies: Overview of Manufacturing Capabilities
  • Table 6.12. FUJIFILM Diosynth Biotechnologies: Future Outlook
  • Table 6.13. Lonza: Company Overview
  • Table 6.14. Lonza: Overview of Manufacturing Capabilities
  • Table 6.15. Lonza: Future Outlook
  • Table 6.16. Merck: Company Overview
  • Table 6.17. Merck: Overview of Manufacturing Capabilities
  • Table 6.18. Merck: Future Outlook
  • Table 6.19. Novasep: Company Overview
  • Table 6.20. Novasep: Overview of Manufacturing Capabilities
  • Table 6.21. Novasep: Future Outlook
  • Table 6.22. Samsung BioLogics: Company Overview
  • Table 6.23. Samsung BioLogics: Overview of Manufacturing Capabilities
  • Table 6.24. Samsung BioLogics: Future Outlook
  • Table 6.25. Synthon: Company Overview
  • Table 6.26. Synthon: Overview of Manufacturing Capabilities
  • Table 6.27. Synthon: Future Outlook
  • Table 7.1. Comparison of Strengths and Weaknesses of Small Molecules and Biologics
  • Table 7.2. Comparison of Development Characteristics of Small Molecules and Biologics
  • Table 8.1. Benchmark Analysis: Peer Groups
  • Table 9.1. Antibody Contract Manufacturing: List of Partnerships, 2013-2019
  • Table 9.2. Antibody Contract Manufacturing Partnerships: Information on Type of Antibodies, Project Scale and Therapeutic Area
  • Table 10.1. Antibody Contract Manufacturing: List of Expansions, 2017-2019
  • Table 10.2. Antibody Contract Manufacturing Expansions: Information on Type of Antibodies
  • Table 14.1. Patent Approval Information of Best-selling Biologics
  • Table 17.1. Antibody Contract Manufacturers: Distribution by Year of Establishment
  • Table 17.2. Antibody Contract Manufacturers: Distribution by Company Size
  • Table 17.3. Antibody Contract Manufacturers: Distribution by Scale of Operation
  • Table 17.4. Antibody Contract Manufacturers: Distribution by Location of Headquarters(Region-wise)
  • Table 17.5. Antibody Contract Manufacturers: Distribution by Location of Headquarters(Country-wise)
  • Table 17.6. Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
  • Table 17.7. Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
  • Table 17.8. Antibody Contract Manufacturers: Distribution by Expression Systems Used
  • Table 17.9. Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
  • Table 17.10. Antibody Contract Manufacturers: Distribution by Regulatory Accreditations /
  • Table 17.11. Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019(till August)
  • Table 17.12. Partnerships: Distribution by Year of Partnership
  • Table 17.13. Partnerships: Distribution by Type of Partnership
  • Table 17.14. Partnerships: Distribution by Year and Type of Partnership
  • Table 17.15. Partnerships: Distribution by Type of Antibody
  • Table 17.16. Partnerships: Distribution by Project Scale
  • Table 17.17. Partnerships: Distribution by Focus Therapeutic Area
  • Table 17.18. Partnerships: Most Active Players
  • Table 17.19. Partnerships: Country-wise Distribution
  • Table 17.20. Recent Expansions: Distribution by Year of Expansion
  • Table 17.21. Recent Expansions: Distribution by Type of Expansion
  • Table 17.22. Recent Expansions: Distribution by Type of Antibody
  • Table 17.23. Recent Expansions: Distribution by Type of Antibody and Expansion
  • Table 17.24. Recent Expansions: Distribution by Location of Facility(Region-wise)
  • Table 17.25. Recent Expansions: Distribution by Location of Facility(Country-wise)
  • Table 17.26. Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
  • Table 17.27. Recent Expansions: Most Active Players
  • Table 17.28. Recent Expansions: Distribution by Local and International Expansions
  • Table 17.29. Antibody Contract Manufacturing: Installed Global Capacity
  • Table 17.30. Antibody Contract Manufacturing Capacity: Distribution by Company Size
  • Table 17.31. Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
  • Table 17.32. Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
  • Table 17.33. Demand Analysis: Annual Demand for Antibodies
  • Table 17.34. Demand Analysis: Annual Demand for Clinical Scale Operations
  • Table 17.35. Demand Analysis: Annual Demand for Commercial Scale Operations
  • Table 17.36. Demand Analysis: Annual Demand in North America
  • Table 17.37. Demand Analysis: Annual Demand in Europe
  • Table 17.38. Demand Analysis: Annual Demand in Asia
  • Table 17.39. Overall Antibody Contract Manufacturing Market, 2020-2030
  • Table 17.40. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody(USD Billion)
  • Table 17.41. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size(USD Billion)
  • Table 17.42. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation(USD Billion)
  • Table 17.43. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used(USD Billion)
  • Table 17.44. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography(USD Billion)
  • Table 17.45. Antibody Contract Manufacturing Market in North America, 2020-2030(USD Billion)
  • Table 17.46. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies(USD Billion)
  • Table 17.47. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies(USD Billion)
  • Table 17.48. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies(USD Billion)
  • Table 17.49. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations(USD Billion)
  • Table 17.50. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations(USD Billion)
  • Table 17.51. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations(USD Billion)
  • Table 17.52. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations(USD Billion)
  • Table 17.53. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations(USD Billion)
  • Table 17.54. Antibody Contract Manufacturing Market in Europe, 2020-2030(USD Billion)
  • Table 17.55. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies(USD Billion)
  • Table 17.56. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies(USD Billion)
  • Table 17.57. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies(USD Billion)
  • Table 17.58. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations(USD Billion)
  • Table 17.59. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations(USD Billion)
  • Table 17.60. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations(USD Billion)
  • Table 17.61. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations(USD Billion)
  • Table 17.62. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations(USD Billion)
  • Table 17.63. Antibody Contract Manufacturing Market in Asia, 2020-2030(USD Billion)
  • Table 17.64. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies(USD Billion)
  • Table 17.65. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies(USD Billion)
  • Table 17.66. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies(USD Billion)
  • Table 17.67. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations(USD Billion)
  • Table 17.68. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations(USD Billion)
  • Table 17.69. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations(USD Billion)
  • Table 17.70. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations(USD Billion)
  • Table 17.71. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations(USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • AbbVie Contract Manufacturing
  • Abcuro
  • Abdi Ibrahim
  • A-Bio Pharma
  • ABL
  • ABL Bio
  • Absolute Antibody
  • Abzena
  • AC Immune
  • Acticor Biotech
  • Actinium Pharmaceuticals
  • Adagene
  • Affinita Biotech
  • Affinity Life Sciences
  • AGC Biologics
  • Ajinomoto Althea
  • Alcami
  • Aldevron
  • Alethia Biotherapeutics
  • Allele Biotechnology & Pharmaceuticals
  • Alligator Bioscience
  • Alvotech
  • Annular Biotech
  • Antibodies Incorporated
  • Antibody Production Services(division of Life Science Group)
  • Arabio
  • Arcus Biosciences
  • argenx
  • ASKA Biotech
  • ASLAN Pharmaceuticals
  • AURA Biotechnologies
  • AutekBio
  • Avid Bioservices
  • Avioq
  • Axcellerate Pharma
  • Batavia Biosciences
  • Baxter BioPharma Solutions
  • Bayer
  • Baylor Scott & White Research Institute
  • BeiGene
  • Bharat Serums and Vaccine
  • BIBITEC
  • BINEX
  • BioInvent International
  • BioLineRx
  • Biomay
  • Biomedical Advanced Research and Development Authority(BARDA)
  • BiosanaPharma
  • Biosynergy EUROPE
  • BioTechnique
  • Biovian
  • BioVolutions
  • BioXcellence(Boehringer Ingelheim)
  • BJ Bioscience
  • Brii Biosciences
  • Bristol-Myers Squibb
  • Bruker
  • Calypso Biotech
  • CANbridge
  • Capralogics
  • Catalent
  • Catalent Biologics
  • Cell Culture Company
  • Cell Essentials
  • Celonic
  • Center of iPS Cell Research and Application, Kyoto University
  • Cerbios-Pharma
  • Changchun High & New Technology Industry
  • ChemPartner
  • Chiome Bioscience
  • CinnaGen
  • Citryll
  • CMAB Biopharma
  • CMC Biologics
  • Cobra Biologics
  • Compugen
  • Cook Pharmica
  • Creative Biolabs
  • CytoDyn
  • Cytovance® Biologics
  • DaTaMabs
  • Diatec Monoclonals
  • DM Bio
  • Dyax
  • Effimune
  • EirGenix
  • Emergent BioSolutions
  • Enzene Biosciences
  • Etinpro
  • EuBiologics
  • Eurofins CDMO
  • Eurogentec
  • exonbio
  • FairJourney Biologics
  • Faron Pharmaceuticals
  • Forty Seven
  • F-star
  • FUJIFILM Diosynth Biotechnologies
  • GlaxoSmithKline
  • Glenmark
  • Goodwin Biotechnology
  • GTP Technology
  • HALIX
  • Harbour BioMed
  • Hong Kong Institute of Biotechnology
  • Horizon Pharma
  • IBC Generium
  • IDT Biologika
  • I-Mab Biopharma
  • Immune Pharmaceuticals
  • Inno Biologics
  • InVivo Biotech
  • JHL Biotech
  • JSR
  • KBI Biopharma
  • Kemwell Biopharma
  • KUBio(a manufacturing unit of GE Healthcare)
  • LakePharma
  • LAMPIRE Biological Laboratories
  • Laureate Biopharmaceutical Services
  • LFB Biomanufacturing
  • Lipum
  • Lonza
  • Lupin
  • Mabion
  • MabPlex
  • MAbSilico
  • Mab-Venture Biopharma
  • MacroGenics
  • Maine Biotechnology Services
  • MassBiologics
  • Medicago
  • MedImmune
  • Medix Biochemica
  • Menarini Biotech
  • Merck
  • Meridian Life Science
  • Merus
  • Mologic
  • MorphoSys
  • Mycenax Biotech
  • Nitto Avecia Pharma Services
  • Northway Biotechpharma
  • Novasep
  • NovoCodex Biopharmaceuticals
  • Omeros
  • OncoQuest
  • OncoSynergy
  • OncoVent
  • OsoBio
  • Pall
  • Pamlico Biopharma
  • Paragon Bioservices(a unit of Catalent Biologics)
  • Particle Sciences(a Lubrizol Company)
  • Pharmedartis
  • Pierre Fabre
  • Pionyr Immunotherapeutics
  • Piramal Pharma Solutions
  • PMI BioPharma Solutions
  • Polymun Scientific
  • Powerway Biotech
  • Praxis Pharmaceutical
  • Precision Biologics
  • Premas Biotech
  • Prestige BioPharma
  • ProBioGen
  • PX'Therapeutics
  • Radimmune Therapeutics
  • ReliaTech
  • Rentschler Biopharma
  • Richter-Helm BioLogics
  • River Vision Development
  • RuiYi
  • Samsung BioLogics
  • Sandoz(a Novartis division)
  • Sanofi
  • SDIX
  • Selexis
  • Selexys Pharmaceuticals(acquired by Novartis)
  • Siam Bioscience
  • Siegfried
  • Sun Pharmaceutical
  • Surface Oncology
  • Suzhou Kintor Pharmaceuticals
  • Symbiosis Pharmaceutical Services
  • Symphogen
  • Syngene(a subsidiary of Biocon)
  • Synthelis
  • Synthon
  • Takara Bio
  • The Native Antigen
  • Therapure Biopharma(Therapure Biomanufacturing)
  • Thermo Fisher Scientific
  • Tizona Therapeutics
  • Tmunity Therapeutics
  • Toyobo Biologics
  • Translational Sciences
  • Trellis Bioscience
  • University College London
  • University of Toyama
  • Vibalogics
  • Vivoryon Therapeutics
  • Wacker Biotech
  • Waisman Biomanufacturing
  • WuXi AppTec
  • WuXi Biologics
  • Xpress Biologics
  • Zymeworks
目次

Example Insights:

In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been linked related to antibodies for use across a number of different disease indications.

Overview:

Since the approval of Orthoclone OKT3® in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. It is worth noting that, till date, more than 100 therapeutic monoclonal antibodies have been approved across different geographies; recent approvals include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (April 2019) and EVENITY™ (April 2019). Owing to their high specificity and the favorable safety profile associated with the therapeutic use of such molecules, antibody based interventions presently constitute the largest class of biologics in the industry. This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragments-based products, are steadily gaining traction. Further, owing to legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements, outsourcing antibody production operations is a popular trend.

The antibody contract manufacturing market is highly competitive, featuring companies of all sizes, some of which claim to offer end-to-end solutions, ranging from antibody development to commercial production. Historical and prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. This dependence on outsourcing can be attributed to the high cost and time investment required to establish the necessary infrastructure and expertise in biologics. The competition among contract manufacturing organizations (CMOs) engaged in this domain is high, with the availability of cutting-edge tools and technologies being one of the key differentiating factors that grant a competitive advantage over other players. Therefore, in order to establish a strong foothold in the market and also meet the growing demand for antibody therapeutics / reagents, CMOs are actively expanding their capacities and capabilities.

Scope of the Report:

The ‘Antibody Contract Manufacturing Market, 2020-2030’ report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies.
  • A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).
  • A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
  • An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013, based on several parameters, such as the year of agreement, type of partnership, project scale and focus therapeutic area.
  • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October), taking into consideration parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), type of antibodies manufactured and location of manufacturing facility.
  • An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).
  • Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the antibody contract manufacturing market. Based on multiple parameters, such as projected growth of overall antibody-based products market, cost of goods sold and direct manufacturing costs, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of antibodies (monoclonal antibodies, bispecific antibodies and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical / clinical and commercial), [E] expression systems (mammalian, microbial and others), and [F] key geographical regions (North America, Europe, Asia). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the antibody contract manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to antibodies, including a brief discussion on the historical evolution of this class of medical products. It highlights the different categories of antibodies, namely monoclonal antibodies, bispecific antibodies and polyclonal antibodies, their potential applications, and mechanisms of action (as therapeutic interventions). In addition, it includes information on the structure of an antibody and its isotypes. Further, the chapter features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the biopharmaceutical industry and its advantages.

Chapter 4 provides an overview of the antibody contract manufacturing landscape. It includes information on over 115 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the CMO, number of manufacturing facilities, as well as location of these facilities, type of antibody manufactured, types of expression systems being used, fill / finish operations and affiliations to regulatory agencies.

Chapter 5 features a company competitiveness analysis of key players engaged in this domain. The analysis compares companies on the basis of their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).

Chapter 6 features detailed profiles of industry players that offer contract manufacturing services at preclinical, clinical and commercial scale and have more than two manufacturing facilities. Each profile provides a brief overview of the company, its contract service offerings, manufacturing capabilities and facilities and an informed future outlook.

Chapter 7 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps and challenges involved in their respective manufacturing processes.

Chapter 8 presents a benchmark analysis, highlighting the capabilities of small, mid-sized and large companies in terms of their service portfolio. Further, the analysis allows companies to compare their existing capabilities within and beyond their respective (geography-based) peer groups, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked amongst players in the time period 2013-2019 (till October). It provides a brief description on the various types of partnership models (which include manufacturing agreements, process development and manufacturing agreements, licensing agreements, acquisitions, joint ventures, service alliances and others) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of agreement, type of partnership, project scale and focus therapeutic area. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents detailed analysis on the recent expansions that have taken place in the antibody contract manufacturing industry, since 2017. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capacity expansion, facility expansion, new facility), type of antibodies (monoclonal antibodies, bispecific antibodies and polyclonal antibodies) and geographical location of the facility.

Chapter 11 features an analysis of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).

Chapter 12 features a detailed analysis of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.

Chapter 13 presents a detailed market forecast analysis, highlighting the likely growth of the antibody contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of antibodies (monoclonal antibodies, bispecific antibodies and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical / clinical and commercial), [E] expression systems (mammalian, microbial and others), and [F] key geographical regions (North America, Europe, Asia).

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of antibody contract manufacturing market, under a SWOT framework.

Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the antibody CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of antibody CMOs.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Dietmar Katinger (Chief Executive Officer, Polymun Scientific), David C Cunningham (Director Corporate Development, Goodwin Biotechnology) and Claire Otjes (Assistant Marketing Manager, Batavia Biosciences).

Chapter 17 is an appendix that contains the list of companies that offer custom manufacturing services for different type of antibodies.

Chapter 18 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Concept of an Antibody
  • 3.3. Structure of an Antibody
  • 3.4. Antibody Isotypes
  • 3.5. Mechanism of Action of Antibodies
  • 3.6. Types of Antibodies
    • 3.6.1. Monoclonal Antibodies
    • 3.6.2. Bispecific Antibodies
    • 3.6.3. Polyclonal Antibodies
  • 3.7. Overview of Contract Manufacturing
  • 3.8. Need for Outsourcing in the Biopharmaceutical Industry
  • 3.9. Advantages of Outsourcing Manufacturing Services

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Antibody Contract Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Scale of Operation
    • 4.2.4. Analysis by Location of Headquarters
    • 4.2.5. Analysis by Location of Manufacturing Facilities
    • 4.2.6. Analysis by Type of Antibodies Manufactured
    • 4.2.7. Analysis by Expression Systems Used
    • 4.2.8. Analysis by Fill / Finish Services Offered
    • 4.2.9. Analysis by Regulatory Accreditations / Certifications

5. COMPANY COMPETITIVE ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Input Parameters
  • 5.3. Methodology
  • 5.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
  • 5.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
  • 5.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. AGC Biologics
    • 6.2.1. Company Overview
    • 6.2.2. Service Portfolio
    • 6.2.3. Manufacturing Facilities and Capabilities
    • 6.2.4. Future Outlook
  • 6.3. Aldevron
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
    • 6.3.3. Manufacturing Facilities and Capabilities
    • 6.3.4. Future Outlook
  • 6.4. BioXcellence (Boehringer Ingelheim)
    • 6.4.1. Company Overview
    • 6.4.2. Service Portfolio
    • 6.4.3. Manufacturing Facilities and Capabilities
    • 6.4.4. Future Outlook
  • 6.5. FUJIFILM Diosynth Biotechnologies
    • 6.5.1. Company Overview
    • 6.5.2. Service Portfolio
    • 6.5.3. Manufacturing Facilities and Capabilities
    • 6.5.4. Future Outlook
  • 6.6. Lonza
    • 6.6.1. Company Overview
    • 6.6.2. Service Portfolio
    • 6.6.3. Manufacturing Facilities and Capabilities
    • 6.6.4. Future Outlook
  • 6.7. Merck
    • 6.7.1. Company Overview
    • 6.7.2. Service Portfolio
    • 6.7.3. Manufacturing Facilities and Capabilities
    • 6.7.4. Future Outlook
  • 6.8. Novasep
    • 6.8.1. Company Overview
    • 6.8.2. Service Portfolio
    • 6.8.3. Manufacturing Facilities and Capabilities
    • 6.8.4. Future Outlook
  • 6.9. Samsung BioLogics
    • 6.9.1. Company Overview
    • 6.9.2. Service Portfolio
    • 6.9.3. Manufacturing Facilities and Capabilities
    • 6.9.4. Future Outlook
  • 6.10. Synthon
    • 6.10.1. Company Overview
    • 6.10.2. Service Portfolio
    • 6.10.3. Manufacturing Facilities and Capabilities
    • 6.10.4. Future Outlook

7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES

  • 7.1. Chapter Overview
  • 7.2. Small Molecule Drugs and Biologics
    • 7.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
    • 7.2.2. Comparison of Key Specifications
    • 7.2.3. Comparison of Manufacturing Processes
    • 7.2.4. Comparison of Key Manufacturing-related Challenges

8. BENCHMARK ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Methodology
  • 8.3. Region-wise Benchmarking
    • 8.3.1. North America, Peer Group I
    • 8.3.2. North America, Peer Group II
    • 8.3.3. North America, Peer Group III
    • 8.3.4. Europe, Peer Group IV
    • 8.3.5. Europe, Peer Group V
    • 8.3.6. Europe, Peer Group VI
    • 8.3.7. Asia, Peer Group VII
    • 8.3.8. Asia, Peer Group VIII
  • 8.4. Concluding Remarks

9. PARTNERSHIPS

  • 9.1. Chapter Overview
  • 9.2. Partnerships Models
  • 9.3. Antibody Contract Manufacturing: List of Partnerships
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Antibody
    • 9.3.5. Analysis by Project Scale
    • 9.3.6. Analysis by Focus Therapeutic Area
    • 9.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership
    • 9.3.8. Geographical Analysis
      • 9.3.8.1. Continent-wise Distribution
      • 9.3.8.2. Country-wise Distribution

10. RECENT EXPANSIONS

  • 10.1. Chapter Overview
  • 10.2. Antibody Contract Manufacturers: List of Expansions
    • 10.2.1. Analysis by Year of Expansion
    • 10.2.2. Analysis by Type of Expansion
    • 10.2.3. Analysis by Type of Antibody
    • 10.2.4. Analysis by Location of Manufacturing Facility
    • 10.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
    • 10.2.6. Analysis of Most Active Players by Number of Expansions
    • 10.2.7. Geographical Analysis
      • 10.2.7.1. Country-wise Distribution

11. CAPACITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Antibody Contract Manufacturers: Installed Global Capacity
    • 11.3.1. Analysis by Company Size
    • 11.3.2. Analysis by Scale of Operation
    • 11.3.3. Analysis by Location of Manufacturing Facility
  • 11.4. Concluding Remarks

12. DEMAND ANALYSIS

  • 12.1 Chapter Overview
  • 12.2 Assumptions and Methodology
  • 12.3 Antibody Contract Manufacturing Market: Overall Annual Demand
    • 12.3.1. Analysis by Scale of Operation
    • 12.3.2. Analysis by Geography

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Forecast Methodology
  • 13.3. Overall Antibody Contract Manufacturing Market, 2020-2030
  • 13.4. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody
  • 13.5. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size
  • 13.6. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
  • 13.7. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used
  • 13.8. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography
    • 13.8.1. Antibody Contract Manufacturing Market in North America, 2020-2030
      • 13.8.1.1. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies
      • 13.8.1.2. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
      • 13.8.1.3. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
      • 13.8.1.4. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
      • 13.8.1.5. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations
      • 13.8.1.6. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
      • 13.8.1.7. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations
      • 13.8.1.8. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations
    • 13.8.2. Antibody Contract Manufacturing Market in Europe, 2020-2030
      • 13.8.2.1. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies
      • 13.8.2.2. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
      • 13.8.2.3. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
      • 13.8.2.4. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
      • 13.8.2.5. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations
      • 13.8.2.6. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations
      • 13.8.2.7. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
      • 13.8.2.8. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations
    • 13.8.3. Antibody Contract Manufacturing Market in Asia, 2020-2030
      • 13.8.3.1. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies
      • 13.8.3.2. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies
      • 13.8.3.3. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies
      • 13.8.3.4. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations
      • 13.8.3.5. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations
      • 13.8.3.6. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations
      • 13.8.3.7. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations
      • 13.8.3.8. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations

14. SWOT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Strengths
  • 14.3. Weaknesses
  • 14.4. Opportunities
  • 14.5. Threats
  • 14.6. Comparison of SWOT Factors
  • 14.7. Concluding Remarks

15. FUTURE OF THE ANTIBODY CMO MARKET

  • 15.1. Chapter Overview
  • 15.2. Outsourcing Activity Anticipated to Witness Significant Growth
  • 15.3. Shift from One-time Contractual Engagements to Strategic Partnerships
  • 15.4. Adoption of New and Innovative Technologies
  • 15.5. Concluding Remarks

16. INTERVIEW TRANSCRIPTS

  • 16.1. Chapter Overview
  • 16.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • 16.3. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • 16.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biopharma
  • 16.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.